$KLRS
Kalaris Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$2.00
▼-8.68%-$0.190
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateKalaris Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is KLRS down today? It is at $2.00 (-8.68%), and our scanner flagged it 11 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment KLRS spikes, and full due diligence on KLRS — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $KLRS 11 times in the last 30 days. Create a free account to track $KLRS, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on KLRS from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
Likely catalystKalaris Therapeutics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filing4Insider trade (Form 4)Aug 28, 2026 · 49 days agoThe company can keep selling new shares into the market. Size not stated in the filing.
Some filings did not state a size, so these are floors.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
17,271,157 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $100.0M in size · Priced at $5.79/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Akkaraju Srinivas Director | Bought (open market) | +244K 1.0% of company | added 12% | 2.22M | $1.2M at $4.83 | May 20, 26 |
Akkaraju Srinivas Director | Sold (automatic/other) | -67K 0.3% of company | sold 0.6% | 10.66M | n/a | May 20, 26 |
Akkaraju Srinivas Director | Acquired (grant/award) | +19K 0.08% of company | added 0.2% | 12.92M | n/a | May 20, 26 |
Hagen Brett R Officer | Sold (automatic/other) | -2K | n/a | n/a | $13K at $6.72 | Mar 20, 26 |
Akkaraju Srinivas Director | Acquired (grant/award) | +1.50M 6.3% of company | added 13% | 12.95M | $15.0M at $10.00 | Dec 22, 25 |
Akkaraju Srinivas Director | Bought (open market) | +480K 2.0% of company | added 3.8% | 12.95M | $5.0M at $10.42 | Dec 18, 25 |
Hagen Brett R Officer | Sold (automatic/other) | -907 | sold 32% | 2K | $8K at $8.97 | Mar 26, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on KLRS from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
KLRS last traded at $2.00, down 8.68% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Kalaris Therapeutics, Inc. Common Stock (KLRS) is next expected to report earnings on Wednesday, November 11, 2026, about 26 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The KLRS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged KLRS 11 times in the last 30 days.
KLRS (Kalaris Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $52M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge KLRS for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$KLRS discussion
Sign in to ask a question or join the discussion.